12:00 AM
 | 
Oct 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Luseogliflozin: Phase III data

The double-blind, Japanese Phase III Study-1 in 158 Type II diabetics showed that once-daily 2.5 mg oral luseogliflozin met the primary endpoint of reducing HabA1c from baseline to week 24 vs. placebo (placebo-adjusted reduction of 0.75%, p<0.001). On...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >